EUCTR2016-003681-34-BG进行中（未招募）1 期
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients with Severe Hemophilia A
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Severe hemophilia A (<1% FVIII:C) according to medical history
- •2. Male patients aged =12 years
- •3. Previous treatment with a FVIII concentrate for at least 150 exposure days (EDs)
- •4. Immunocompetence (CD4+ count >200/µL)
- •5. Good documentation of the historical bleeding rate (at least for the 6 months pre-ceding study start)
- •6. Voluntarily given, fully informed written and signed consent obtained by the pa-tient (or parent/legal guardian in case of adolescents) before any study-related pro-cedures are conducted
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Any coagulation disorders other than hemophilia A
- •2. History of FVIII inhibitor activity (=0.6 BU) or detectable FVIII inhibitory anti-bodies (=0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory
- •3. Severe liver or kidney diseases (alanine aminotransferase [ALAT] and aspartate transaminase [ASAT] levels >5 times of upper limit of normal, creatinine
- •>120 µmol/L)
- •4. Patients receiving or scheduled to receive immunomodulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs
- •5. Treatment with any investigational medicinal product in another interventional clinical study currently or within 4 weeks before enrollment
研究者
相似试验
进行中（未招募）
1 期
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-003681-34-PLOctapharma AG55
进行中（未招募）
1 期
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 19.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-003681-34-HUOctapharma AG55
进行中（未招募）
不适用
To determine the pharmacokinetics of human-cl rhFVIII in terms of the FVIII coagulant activity (FVIII:C) and to compare it with the licensed FVIII concentrate Kogenate/Helixate in previously treated subjects suffering from severe hemophilia A.EUCTR2008-001563-11-BGOctapharma AG22
进行中（未招募）
不适用
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A.Severe hemophilia A (FVIII:C <1%)EUCTR2008-001563-11-DEOctapharma AG25
已完成
不适用
Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN87293301Octapharma AG (Switzerland)20